FDA approves novel treatment for hairy cell leukemia
(HealthDay)—Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday.
Sep 15, 2018
0
3